BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 16038739)

  • 1. Imatinib therapy in Hypereosinophilic Syndrome: a case of molecular remission.
    Cervetti G; Galimberti S; Carulli G; Petrini M
    Leuk Res; 2005 Sep; 29(9):1097-8. PubMed ID: 16038739
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib-mesylate for all patients with hypereosinophilic syndrome?
    Musto P; Perla G; Minervini MM; Carella AM; Coco FL; Catalano G
    Leuk Res; 2004 Jul; 28(7):773-4. PubMed ID: 15158099
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapid reversal of quadraparesis in chronic eosinophilic leukaemia expressing the FIP1L1-PDGFRA transcript after therapy with imatinib.
    Hus M; Helbig G; Cioch M; Szczepanska-Szerej H; Wieczorek P; Woźniak M; Kozinska J; Morawska M; Dmoszynska A; Kyrcz-Krzemien S; Kata D
    Leuk Res; 2011 Mar; 35(3):e15-7. PubMed ID: 21093052
    [No Abstract]   [Full Text] [Related]  

  • 4. Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission.
    Malagola M; Martinelli G; Rondoni M; Ottaviani E; Piccaluga PP; Ricci P; Visani G; Baccarani M
    Haematologica; 2004 Aug; 89(8):ECR25. PubMed ID: 15339694
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of idiopathic hypereosinophilic syndrome with imatinib].
    Sørensen AL; Larsen H
    Ugeskr Laeger; 2008 Jan; 170(4):254. PubMed ID: 18282461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft.
    Rose C; Dupire S; Roche-Lestienne C; Grardel N; Bourgeois E; Cambier N; Preudhomme C
    Leukemia; 2004 Feb; 18(2):354-5. PubMed ID: 14671642
    [No Abstract]   [Full Text] [Related]  

  • 7. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia.
    Curtis CE; Grand FH; Musto P; Clark A; Murphy J; Perla G; Minervini MM; Stewart J; Reiter A; Cross NC
    Br J Haematol; 2007 Jul; 138(1):77-81. PubMed ID: 17555450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapy.
    Krauth MT; Binder T; Ohler L; Jäger U; Valent P
    Leuk Res; 2008 Nov; 32(11):1779-83. PubMed ID: 18417214
    [No Abstract]   [Full Text] [Related]  

  • 9. [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].
    Moles MP; Landry J; Roche-Lestienne C; Godon A; Schmidt-Tanguy A; Gardembas M; Le Clech C; Verret JL; Zandecki M; Blanchet O
    Ann Biol Clin (Paris); 2005; 63(3):317-22. PubMed ID: 15951264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term remission of lymphocytic hypereosinophilic syndrome with imatinib mesylate.
    Christoforidou A; Kotsianidis I; Margaritis D; Anastasiadis A; Douvali E; Tsatalas C
    Am J Hematol; 2012 Jan; 87(1):131-2. PubMed ID: 21919038
    [No Abstract]   [Full Text] [Related]  

  • 11. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.
    Walz C; Curtis C; Schnittger S; Schultheis B; Metzgeroth G; Schoch C; Lengfelder E; Erben P; Müller MC; Haferlach T; Hochhaus A; Hehlmann R; Cross NC; Reiter A
    Genes Chromosomes Cancer; 2006 Oct; 45(10):950-6. PubMed ID: 16845659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib.
    Hofmann SC; Technau K; Müller AM; Lübbert M; Bruckner-Tuderman L
    J Am Acad Dermatol; 2007 May; 56(5 Suppl):S68-72. PubMed ID: 17097375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.
    Mehr S; Rego S; Kakakios A; Kilham H; Kemp A
    J Pediatr; 2009 Aug; 155(2):289-91. PubMed ID: 19619754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A man with FIP1L1/PDGFRA-positive chronic eosinophilic leukemia].
    Leeksma OC; de Ruiter GS; van der Hulst VP; Terpstra WE; Cools J; Vandenberghe P
    Ned Tijdschr Geneeskd; 2006 Sep; 150(35):1936-43. PubMed ID: 16999279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
    Garg A; Duggal L; Aggarwal S; Jain N
    J Assoc Physicians India; 2006 Nov; 54():883-6. PubMed ID: 17249259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clonal hypereosinophilic syndrome with specific and effective therapy: a report of two cases.
    Ellis MH; Ashur-Fabian O; Trakhtenbrot L; Amariglio N
    Isr Med Assoc J; 2006 Dec; 8(12):836-7. PubMed ID: 17214097
    [No Abstract]   [Full Text] [Related]  

  • 17. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
    Arancibia AM; Bendit I; Epelman S
    Pediatr Blood Cancer; 2008 May; 50(5):1078. PubMed ID: 18085674
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful treatment with imatinib mesylate of hypereosinophilic syndrome (chronic eosinophilic leukemia) with myelofibrosis.
    Ishii Y; Ito Y; Kuriyama Y; Tauchi T; Ohyashiki K
    Leuk Res; 2004 May; 28 Suppl 1():S79-80. PubMed ID: 15036947
    [No Abstract]   [Full Text] [Related]  

  • 19. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
    Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
    Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Glivek in the therapy of some forms of Ph- and bcr/abl-negative myeloproliferative diseases and a myeloproliferative variant of idiopathic hypereosinophilic syndrome].
    Nemchenko IS; Khoroshko ND; Turkina AG; Vinogradova OIu; Sokolova MA; Abakumov EM; Semenova EA; Zakharova AV; Domracheva EV
    Ter Arkh; 2004; 76(7):87-90. PubMed ID: 15379136
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.